See more : PT Sky Energy Indonesia Tbk (JSKY.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Aclaris Therapeutics, Inc. (ACRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aclaris Therapeutics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Dynex Capital, Inc. (DX-PC) Income Statement Analysis – Financial Results
- Golden Star Acquisition Corporation (GODN) Income Statement Analysis – Financial Results
- Jeevan Scientific Technology Limited (JSTL.BO) Income Statement Analysis – Financial Results
- Reliance Infrastructure Limited (RELINFRA.BO) Income Statement Analysis – Financial Results
- D.P. Wires Limited (DPWIRES.NS) Income Statement Analysis – Financial Results
Aclaris Therapeutics, Inc. (ACRS)
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.25M | 29.75M | 6.76M | 6.48M | 4.23M | 10.09M | 1.68M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 18.08M | 11.96M | 4.71M | 5.13M | 4.06M | 6.85M | 1.21M | 120.00K | 90.00K | 0.00 | 0.00 |
| Gross Profit | 13.17M | 17.79M | 2.05M | 1.35M | 172.00K | 3.24M | 476.00K | -120.00K | -90.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 42.14% | 59.80% | 30.29% | 20.81% | 4.07% | 32.12% | 28.28% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.38M | 77.81M | 43.81M | 31.73M | 64.90M | 63.01M | 39.79M | 33.48M | 15.34M | 6.51M | 3.49M |
| General & Administrative | 31.10M | 25.13M | 23.62M | 20.53M | 27.16M | 27.65M | 33.11M | 15.09M | 5.33M | 2.03M | 1.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 283.00K | 671.00K | 48.00M | 85.00K | 3.30M | 0.00 | 0.00 | 0.00 |
| SG&A | 31.10M | 25.13M | 23.62M | 20.53M | 27.83M | 75.65M | 33.11M | 15.09M | 5.33M | 2.03M | 1.77M |
| Other Expenses | 0.00 | 2.95M | -1.14M | -424.00K | -2.48M | 2.68M | 2.07M | 488.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 130.80M | 102.95M | 67.43M | 52.26M | 92.73M | 138.66M | 72.90M | 48.57M | 20.67M | 8.53M | 5.26M |
| Cost & Expenses | 128.61M | 114.91M | 72.15M | 57.39M | 96.78M | 145.51M | 74.11M | 48.57M | 20.67M | 8.53M | 5.26M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 104.00K | 16.00K | 21.00K |
| Interest Expense | 0.00 | 4.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 863.00K | 797.00K | 923.00K | 1.32M | 1.59M | 1.32M | 402.00K | 120.00K | 90.00K | 12.00K | 11.00K |
| EBITDA | -117.57M | -84.36M | -65.06M | -48.20M | -90.84M | -80.78M | -53.45M | -48.57M | -20.67M | -8.52M | -5.25M |
| EBITDA Ratio | -376.22% | -267.74% | -607.08% | -785.44% | -1,751.83% | -1,341.93% | -4,303.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -97.36M | -85.15M | -65.38M | -50.91M | -111.06M | -135.41M | -72.42M | -48.57M | -20.67M | -8.53M | -5.26M |
| Operating Income Ratio | -311.55% | -286.21% | -967.08% | -785.44% | -2,627.35% | -1,341.93% | -4,303.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.51M | 2.95M | -1.14M | -424.00K | -2.48M | 2.68M | -15.99M | 488.00K | 104.00K | 16.00K | 21.00K |
| Income Before Tax | -88.85M | -86.91M | -90.87M | -51.34M | -113.54M | -132.74M | -70.35M | -48.08M | -20.56M | -8.52M | -5.24M |
| Income Before Tax Ratio | -284.32% | -292.11% | -1,343.96% | -791.98% | -2,686.11% | -1,315.41% | -4,180.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -367.00K | 1.75M | 23.42M | -182.00K | 29.31M | 2.68M | -1.83M | -120.00K | -90.00K | 0.00 | 0.00 |
| Net Income | -88.48M | -88.66M | -114.28M | -51.15M | -142.85M | -132.74M | -68.52M | -48.08M | -20.56M | -8.52M | -5.24M |
| Net Income Ratio | -283.15% | -298.00% | -1,690.30% | -789.17% | -3,379.47% | -1,315.41% | -4,071.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.27 | -1.36 | -2.01 | -1.20 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.80 | -0.49 |
| EPS Diluted | -1.27 | -1.36 | -2.01 | -1.20 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.80 | -0.49 |
| Weighted Avg Shares Out | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.10M | 21.42M | 6.11M | 10.66M | 10.66M |
| Weighted Avg Shares Out (Dil) | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.10M | 21.42M | 6.11M | 10.66M | 10.66M |
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective December 2, 2024, the Compensation Committee of...
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside...
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
On Monday, Aclaris Therapeutics, Inc. ACRS entered into an exclusive license agreement with Biosion Inc for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclinical-stage, novel bispecific antibody directed against both TSLP and IL4R.
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed $900M with tiered...
Aclaris Therapeutics Announces $80 Million Private Placement
WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase...
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
- Enhances Aclaris' pipeline with complementary biologics portfolio - - Expands leadership team with addition of seasoned biotech executives - - Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) --...
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.41 per share a year ago.
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside...
Source: https://incomestatements.info
Category: Stock Reports